ADVAIR DISKUS
ICSLABA DPI
Fluticasone propionate / Salmeterol · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone propionate ICS100 mcg, 250 mcg, or 500 mcg per blister
Synthetic corticosteroid with potent anti-inflammatory activity. Inhibits multiple cell types (mast cells, eosinophils, basophils, macrophages) and mediators (histamine, leukotrienes, cytokines) involved in asthmatic and COPD airway inflammation.
- Salmeterol xinafoate LABA50 mcg per blister (as salmeterol xinafoate)
Long-acting beta2-adrenergic agonist (LABA). Stimulates beta2-receptors on airway smooth muscle, increasing intracellular cAMP and producing prolonged bronchodilation (≥12 hours).
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaCOPD
100/50 mcg
1 inhalation twice daily (morning and evening, ~12 hours apart) → 200/100 mcg
FDA Approved
Starting dose for patients not currently on an ICS, or patients on low-dose ICS.
Not Approved
The 100/50 strength is NOT indicated for COPD. Only 250/50 is approved for COPD.
250/50 mcg
1 inhalation twice daily → 500/100 mcg
FDA Approved
For patients not adequately controlled on medium-dose ICS.
FDA Approved
Maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema. Also to reduce exacerbations.
500/50 mcg
1 inhalation twice daily → 1000/100 mcg
FDA Approved
For patients not adequately controlled on high-dose ICS.
Not Approved
The 500/50 strength is NOT indicated for COPD. Only 250/50 is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
100/50 mcg 1 inhalation twice daily (morning and evening, ~12 hours apart) → 200/100 mcg
Asthma FDA Approved
Starting dose for patients not currently on an ICS, or patients on low-dose ICS.
COPD Not Approved
The 100/50 strength is NOT indicated for COPD. Only 250/50 is approved for COPD.
250/50 mcg 1 inhalation twice daily → 500/100 mcg
Asthma FDA Approved
For patients not adequately controlled on medium-dose ICS.
COPD FDA Approved
Maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema. Also to reduce exacerbations.
500/50 mcg 1 inhalation twice daily → 1000/100 mcg
Asthma FDA Approved
For patients not adequately controlled on high-dose ICS.
COPD Not Approved
The 500/50 strength is NOT indicated for COPD. Only 250/50 is approved for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Onset of action is too slow for rescue. Use a SABA (e.g., albuterol).
Related Inhalers
Same active ingredients (Fluticasone/Salmeterol)